Harrow Health Company Insiders
| HROW Stock | USD 12.35 0.30 2.37% |
Harrow Health's insiders are aggressively buying. The analysis of insiders' sentiment of trading Harrow Health stock suggests that vertually all insiders are extremely bullish at this time. Harrow Health employs about 315 people. The company is managed by 21 executives with a total tenure of roughly 78 years, averaging almost 3.0 years of service per executive, having 15.0 employees per reported executive.
| Mark Baum CEO CEO, Director |
| Robert Kammer Chairman Independent Chairman of the Board |
Harrow Health's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-03-28 | Opaleye Management Inc. | Acquired 50000 @ 12.82 | View | ||
| 2024-03-22 | Mark L Baum | Acquired 9000 @ 11.59 | View | ||
| 2024-03-20 | Opaleye Management Inc. | Acquired 50600 @ 9.65 | View | ||
| 2023-11-16 | Mark L Baum | Acquired 7500 @ 8.11 | View | ||
| 2023-09-19 | Opaleye Management Inc. | Acquired 14017 @ 14.65 | View | ||
| 2023-08-14 | Martin A Makary | Acquired 20000 @ 16.92 | View |
Monitoring Harrow Health's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Harrow |
Harrow Health's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Harrow Health's future performance. Based on our forecasts, it is anticipated that Harrow will maintain a workforce of slightly above 320 employees by May 2024.Harrow Health Management Team Effectiveness
Return On Capital Employed is likely to climb to 0 in 2024, whereas Return On Tangible Assets are likely to drop (0.17) in 2024. At this time, Harrow Health's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 146 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (2 M). Harrow Health's management efficiency ratios could be used to measure how well Harrow Health manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to climb to about 34.2 M in 2024, despite the fact that Net Loss is likely to grow to (12 M).
Harrow Health Workforce Comparison
Harrow Health is rated # 5 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 29,844. Harrow Health claims roughly 315 in number of employees contributing just under 2% to equities under Health Care industry.
Harrow Health Profit Margins
The company has Profit Margin (PM) of (0.19) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.12.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.47 | 0.6955 |
|
|
Harrow Health Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Harrow Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Harrow Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Harrow Health insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 1.2222 | 11 | 9 | 368,638 | 343,732 |
| 2023-12-01 | 1.5 | 3 | 2 | 52,500 | 29,778 |
| 2023-09-01 | 1.1667 | 7 | 6 | 1,431,800 | 1,931,398 |
| 2023-06-01 | 4.0 | 8 | 2 | 1,596,976 | 297,633 |
| 2023-03-01 | 0.5 | 3 | 6 | 201,000 | 280,223 |
| 2022-09-01 | 2.0 | 2 | 1 | 11,085 | 40,000 |
| 2022-03-01 | 0.8333 | 5 | 6 | 231,343 | 342,934 |
| 2021-09-01 | 5.0 | 15 | 3 | 1,531,001 | 23,900 |
| 2021-06-01 | 2.0 | 10 | 5 | 1,090,660 | 1,371,461 |
| 2021-03-01 | 1.6667 | 5 | 3 | 455,000 | 237,500 |
| 2020-09-01 | 1.6667 | 10 | 6 | 355,298 | 93,798 |
| 2020-06-01 | 15.0 | 15 | 1 | 778,924 | 600,000 |
| 2020-03-01 | 0.75 | 6 | 8 | 467,718 | 457,719 |
| 2019-12-01 | 0.5 | 2 | 4 | 195,000 | 208,000 |
| 2019-06-01 | 1.3333 | 4 | 3 | 38,860 | 30,000 |
| 2019-03-01 | 1.6667 | 5 | 3 | 350,000 | 30,000 |
| 2018-03-01 | 2.5 | 5 | 2 | 310,000 | 60,000 |
| 2017-06-01 | 2.3333 | 7 | 3 | 317,892 | 255,000 |
| 2017-03-01 | 4.0 | 4 | 1 | 322,000 | 20,000 |
| 2016-12-01 | 4.0 | 8 | 2 | 885,000 | 283,709 |
| 2016-06-01 | 5.0 | 10 | 2 | 1,570,950 | 1,207,500 |
| 2016-03-01 | 4.0 | 4 | 1 | 150,000 | 15,000 |
| 2015-06-01 | 2.3333 | 7 | 3 | 78,207 | 425,282 |
| 2015-03-01 | 2.0 | 4 | 2 | 307,500 | 25,000 |
| 2014-09-01 | 2.0 | 6 | 3 | 98,367 | 90,465 |
| 2012-12-01 | 0.5 | 1 | 2 | 38,014 | 0.00 |
| 2012-09-01 | 1.0 | 7 | 7 | 6,371,623 | 15,979,883 |
| 2012-06-01 | 2.0 | 14 | 7 | 23,285,286 | 778,812 |
| 2012-03-01 | 0.6667 | 8 | 12 | 3,133,261 | 13,266,761 |
| 2011-12-01 | 0.25 | 1 | 4 | 493.00 | 4,928 |
| 2009-12-01 | 1.0 | 1 | 1 | 215,000 | 85,000 |
| 2008-12-01 | 5.0 | 5 | 1 | 290,000 | 10,000 |
| 2008-09-01 | 3.5 | 7 | 2 | 7,900 | 20,000 |
| 2008-06-01 | 3.0 | 3 | 1 | 304,200 | 300,000 |
Harrow Health Notable Stakeholders
A Harrow Health stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Harrow Health often face trade-offs trying to please all of them. Harrow Health's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Harrow Health's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Baum | CEO, Director | Profile | |
| Robert Kammer | Independent Chairman of the Board | Profile | |
| John Saharek | President of ImprimisRx | Profile | |
| Andrew Boll | CFO, Secretary | Profile | |
| CMA CFA | CFO Secretary | Profile | |
| Anthony Principi | Independent Director | Profile | |
| Richard Lindstrom | Director | Profile | |
| Stephen Austin | Independent Director | Profile | |
| Robert DDS | Special Advisor | Profile | |
| Jamie Webb | Director Relations | Profile | |
| Larry Dillaha | Chief Medical Officer | Profile | |
| David Moufarrge | VP Technology | Profile | |
| RPh Mannebach | Head Pharmacovigilance | Profile | |
| CFA CMA | CFO Sec | Profile | |
| Andrew Livingston | Chief Officer | Profile | |
| Larry MD | Chief Officer | Profile | |
| Mark JD | CEO Chairman | Profile | |
| Kim Barratt | Chief Officer | Profile | |
| Dennis Saadeh | Chief of Formulation Strategy | Profile | |
| John MBA | Chief Officer | Profile | |
| Dennis PharmD | Chief Strategy | Profile |
About Harrow Health Management Performance
The success or failure of an entity such as Harrow Health often depends on how effective the management is. Harrow Health management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Harrow management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Harrow management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | 0 | 0 | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.35) | (0.36) |
The data published in Harrow Health's official financial statements usually reflect Harrow Health's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Harrow Health. For example, before you start analyzing numbers published by Harrow accountants, it's critical to develop an understanding of what Harrow Health's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Harrow Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Harrow Health's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Harrow Health's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Harrow Health. Please utilize our Beneish M Score to check the likelihood of Harrow Health's management manipulating its earnings.
Harrow Health Workforce Analysis
Traditionally, organizations such as Harrow Health use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Harrow Health within its industry.Harrow Health Manpower Efficiency
Return on Harrow Health Manpower
| Revenue Per Employee | 413.3K | |
| Revenue Per Executive | 6.2M | |
| Net Loss Per Employee | 77.5K | |
| Net Loss Per Executive | 1.2M | |
| Working Capital Per Employee | 286.2K | |
| Working Capital Per Executive | 4.3M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Harrow Stock please use our How to Invest in Harrow Health guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Harrow Stock analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Harrow Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Earnings Share (0.75) | Revenue Per Share 3.992 | Quarterly Revenue Growth 0.788 | Return On Assets 0.0022 |
The market value of Harrow Health is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.